Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 基蛋生物科技股份有限公司(股票代码603387)成立于2002年3月,总部位于南京,2017年7月在上海证券交易所主板上市。 公司始终专注于体外诊断产品的研发、生产、销售和服务;相继建立了胶体金免疫层析、荧光免疫层析、生化、化学发光、血细胞分析、止血与血栓检测、分子诊断技术和诊断试剂原材料开发八大技术平台;配套的现代化加工中心,BSIISO13485质量管理体系认证和CE认证,保证了产品的质量及全产业链布局;遍布世界各地的子公司和办事处组成的全球营销网络,令公司优质的产品畅销120余个国家,受到国内外客户的广泛赞誉。 目前,公司拥有授权专利300余项,自主产品注册证国内外共计1120余个,覆盖心血管疾病、肾损伤、糖尿病、妊娠、传染病、肿瘤等多个领域,广泛应用于各级医疗机构。 未来,公司将在继续保持POCT领先的同时,稳步开拓生化、化学发光、血球、凝血、微生物检测、分子诊断、实验室自动化整体解决方案等板块,矢志成为具国际竞争力的生物科技企业,为提高人类健康医疗水平做贡献。 | ||||||||||||||||||||||||
Main Business | 专注于体外诊断试剂与仪器的研发、生产、销售及服务。 | ||||||||||||||||||||||||
Legal Representative | 苏恩本 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 刘葱 | ||||||||||||||||||||||||
Solicitors | 北京懋德律师事务所 | ||||||||||||||||||||||||
Auditors | 瑞华会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 025-68568577 | ||||||||||||||||||||||||
Fax No | 025-68568577 | ||||||||||||||||||||||||
Website | www.getein.com.cn | ||||||||||||||||||||||||
IR@getein.cn | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 17/07/2017 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 0.550 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 0.200 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 5.046 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 4.301B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |